文献速递神经免疫

法国那他珠单抗使用者中进行性多灶性白质脑病发病率与风险分层

Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
PubMed 文献 · JAMA Neurol · 2020-01-01

2013年前PML发病率每年显著增加45.3%,2013至2016年每年显著下降23.0%,提示风险最小化建议与JC病毒血清学检测的推广可能相关。

要点

  • 2007至2016年总体粗发病率为2.00/1000患者年(95%CI 1.46-2.69)。

核心结论

  • 研究首次提示法国那他珠单抗相关PML发病率自2013年起下降,可能与JC病毒血清学检测的普遍使用相关。

研究设计与样本

  • 纳入6318例至少接受1次那他珠单抗输注的多发性硬化患者,其中女性4682例(74.1%)。
  • 向所有中心发放问卷以了解PML风险分层实践,数据分析于2018年7月进行。

临床怎么用

  • 结果支持继续并加强多发性硬化疾病修正治疗管理中的教育活动和风险最小化策略。
  • JC病毒血清学检测可能有助于那他珠单抗相关PML的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Risk of developing progressive multifocal leukoencephalopathy (PML) is the major barrier to using natalizumab for patients with multiple sclerosis (MS). To date, the association of risk stratification with PML incidence has not been evaluated. OBJECTIVE: To describe the temporal evolution of PML incidence in France before and after introduction of risk minimization recommendations in 2013. DESIGN, SETTING, AND PARTICIPANTS: This observational study used data in the MS registry OFSEP (Observatoire Français de la Sclérose en Plaques) collected between April 15, 2007, and December 31, 2016, by participating MS expert centers and MS-dedicated networks of neurologists in France. Patients with an MS diagnosis according to current criteria, regardless of age, were eligible, and those exposed to at least 1 natalizumab infusion (n = 6318) were included in the at-risk population. A questionnaire was sent to all centers, asking for a description of their practice regarding PML risk stratification. Data were analyzed in July 2018. EXPOSURES: Time from the first natalizumab infusion to the occurrence of PML, natalizumab discontinuation plus 6 months, or the last clinical evaluation. MAIN OUTCOMES AND MEASURES: Incidence was the number of PML cases reported relative to the person-years exposed to natalizumab. A Poisson regression model for the 2007 to 2016 period estimated the annual variation in incidence and incidence rate ratio (IRR), adjusted for sex and age at treatment initiation and stratified by period (2007-2013 and 2013-2016). RESULTS: In total, 6318 patients were exposed to natalizumab during the study period, of whom 4682 (74.1%) were female, with a mean (SD [range]) age at MS onset of 28.5 (9.1 [1.1-72.4]) years; 45 confirmed incident cases of PML were diagnosed in 22 414 person-years of exposure. The crude incidence rate for the whole 2007 to 2016 period was 2.00 (95% CI, 1.46-2.69) per 1000 patient-years. Incidence significantly increased by 45.3% (IRR, 1.45; 95% CI, 1.15-1.83; P = .001) each year before 2013 and decreased by 23.0% (IRR, 0.77; 95% CI, 0.61-0.97; P = .03) each year from 2013 to 2016. CONCLUSIONS AND RELEVANCE: The results of this study suggest, for the first time, a decrease in natalizumab-associated PML incidence since 2013 in France that may be associated with a generalized use of John Cunningham virus serologic test results; this finding appears to support the continuation and reinforcement of educational activities and risk-minimization strategies in the management of disease-modifying therapies for multiple sclerosis.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Vukusic S, Rollot F, Casey R, et al. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurol. 2020. PMID: 31479149. doi:10.1001/jamaneurol.2019.2670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。